Nov 07, 2023 / NTS GMT
Yatin Suneja - Guggenheim Partners - Analyst
Good morning, everyone. Myself, Yatin Suneja. I'm one of the biotech analysts here at Guggenheim. It is my pleasure to welcome each one of you at our fifth annual I&I conference. This is day two.
Our first presenting company for the day is Spyre. From the company, we have Cameron Turtle, who is the Chief Operating Officer. It's a relatively newer company. Recent reverse merger or the reverse merger is in the process right now.
I will hand it over to Cameron maybe to just give us an overview of the company, just talk about the founding of the company, what are some of the key up-and-coming milestones. Maybe spend five minutes on that, and then I have a set of questions that I want to run through.
So Cameron, that's all yours.
Cameron Turtle - Aeglea BioTherapeutics, Inc. - COO
All right. Thanks, Yatin, and thanks for having us. Thanks, everyone, for the time this morning.
So as you mentioned, we just launched Spyre earlier this year. And I think, really, the goal here -- it's a
Aeglea Bio Therapeutics Inc at Guggenheim Securities Inflammation & Immunology Conference Transcript
Nov 07, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers